PPRC1

Summary

PPRC1 (PPARG related coactivator 1, HGNC:30025) is a protein-coding gene on chromosome 10q24.32, encoding Peroxisome proliferator-activated receptor gamma coactivator-related protein 1 (Q5VV67). Acts as a coactivator during transcriptional activation of nuclear genes related to mitochondrial biogenesis and cell growth. It is a selective cancer dependency (DepMap: 48.2% of cell lines).

The protein encoded by this gene is similar to PPAR-gamma coactivator 1 (PPARGC1/PGC-1), a protein that can activate mitochondrial biogenesis in part through a direct interaction with nuclear respiratory factor 1 (NRF1). This protein has been shown to interact with NRF1. It is thought to be a functional relative of PPAR-gamma coactivator 1 that activates mitochondrial biogenesis through NRF1 in response to proliferative signals. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 23082 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 276 total
• Cancer dependency (DepMap): dependent in 48.2% of screened cell lines
• MANE Select transcript: NM_015062

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30025
Approved symbol	PPRC1
Name	PPARG related coactivator 1
Location	10q24.32
Locus type	gene with protein product
Status	Approved
Aliases	PRC, KIAA0595, MGC74642
Ensembl gene	ENSG00000148840
Ensembl biotype	protein_coding
OMIM	617462
Entrez	23082

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 16 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000278070, ENST00000370012, ENST00000413464, ENST00000462933, ENST00000489648, ENST00000495914, ENST00000878002, ENST00000878003, ENST00000878004, ENST00000878005, ENST00000878006, ENST00000930415, ENST00000930416, ENST00000930417, ENST00000930418, ENST00000930419, ENST00000930420, ENST00000930421, ENST00000930422

RefSeq mRNA: 3 — MANE Select: NM_015062 NM_001288727, NM_001288728, NM_015062

CCDS: CCDS73186, CCDS7529

Canonical transcript exons

ENST00000278070 — 14 exons

Exon	Start	End
ENSE00000933206	102138879	102138980
ENSE00000987562	102138619	102138765
ENSE00001100780	102139100	102142004
ENSE00001100791	102149178	102149329
ENSE00001100792	102145020	102145090
ENSE00001100799	102146672	102147392
ENSE00001695787	102137850	102138038
ENSE00001813264	102149926	102150333
ENSE00002322993	102133040	102133221
ENSE00003487122	102148372	102148521
ENSE00003495469	102148817	102148938
ENSE00003610827	102148628	102148694
ENSE00003622260	102143045	102143098
ENSE00003679315	102144250	102144307

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 93.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.0297 / max 423.3553, expressed in 1804 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106680	17.3708	1802
106682	0.6590	402

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left uterine tube	UBERON:0001303	93.87	gold quality
oocyte	CL:0000023	92.50	gold quality
skin of abdomen	UBERON:0001416	91.34	gold quality
left ovary	UBERON:0002119	91.33	gold quality
upper lobe of left lung	UBERON:0008952	91.33	gold quality
right ovary	UBERON:0002118	91.32	gold quality
omental fat pad	UBERON:0010414	91.19	gold quality
peritoneum	UBERON:0002358	91.14	gold quality
lower esophagus mucosa	UBERON:0035834	91.01	gold quality
upper lobe of lung	UBERON:0008948	90.86	gold quality
adenohypophysis	UBERON:0002196	90.55	gold quality
secondary oocyte	CL:0000655	90.34	gold quality
skin of leg	UBERON:0001511	90.31	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.10	gold quality
adipose tissue of abdominal region	UBERON:0007808	90.05	gold quality
body of pancreas	UBERON:0001150	90.01	gold quality
muscle layer of sigmoid colon	UBERON:0035805	89.93	gold quality
cartilage tissue	UBERON:0002418	89.82	gold quality
esophagus mucosa	UBERON:0002469	89.69	gold quality
mucosa of stomach	UBERON:0001199	89.64	gold quality
ectocervix	UBERON:0012249	89.61	gold quality
body of uterus	UBERON:0009853	89.60	gold quality
body of stomach	UBERON:0001161	89.17	gold quality
tibial nerve	UBERON:0001323	89.14	gold quality
mucosa of transverse colon	UBERON:0004991	89.14	gold quality
esophagus	UBERON:0001043	89.10	gold quality
stromal cell of endometrium	CL:0002255	89.07	gold quality
endocervix	UBERON:0000458	89.00	gold quality
lower esophagus muscularis layer	UBERON:0035833	88.89	gold quality
lower esophagus	UBERON:0013473	88.86	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.92

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF

miRNA regulators (miRDB)

20 targeting PPRC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-3164	99.02	68.39	1071
HSA-MIR-6820-3P	99.02	68.50	1035
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-6783-5P	97.67	67.21	1528
HSA-MIR-1306-5P	97.11	64.04	755

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 48.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 17)

• PRC is a functional relative of PGC-1 that operates through NRF-1 and possibly other activators in response to proliferative signals (PMID:11340167)
• overexpression of the PRC pathway is responsible for mitochondrial proliferation in the context of thyroid oncocytoma (PMID:14550271)
• PGC-1 has a role in regulating gluconeogenic genes along with HNF-4alpha and SREBP-1 (PMID:14722127)
• Coordinate regulation of nucleus-encoded mitochondrial transcription factors by NRFs and PGC-1 family coactivators is essential to the control of mitochondrial biogenesis (PMID:15684387)
• This review focuses on the biologic and physiologic functions of the PGC-1 coactivators, with particular emphasis on striated muscle, liver, and other organ systems relevant to common diseases such as diabetes and heart failure. (PMID:16511594)
• Upregulation of PGC-1alpha and PGC-1beta in the colorectal tumor cells can be part of an adaptation mechanism to help overcome the severe consequences of mtDNA mutations on oxidative phosphorylation. (PMID:17341490)
• These results revealed that bile acid inhibits the promoter activity of PGC-1 in an SHP-dependent manner. (PMID:17390079)
• Activation of the SIRT1/PGC-1 pathway, in a metabolic context promotes mitochondrial function and this pathway plays a role in neurodegerative disease. Review. (PMID:17937892)
• The results are consistent with a pathway whereby PRC regulates NRF-2-dependent genes through a multiprotein complex involving HCF-1. (PMID:18343819)
• support a role for PRC in the integration of pathways directing mitochondrial respiratory function and cell growth (PMID:19036724)
• PRC has a role in the rapid modulation of metabolic functions in response to the status of the cell cycle (PMID:19956726)
• A general role for PRC in the adaptive response to cellular dysfunction. (PMID:23364789)
• PRC is a negative regulator of endothelial inflammation; it negatively regulates endothelial adhesion of monocytes via inhibition of NF kappaB activity (PMID:23954632)
• PRC and c-MYC can act in concert through Akt-GSK-3 signaling to reprogram gene expression in response to mitochondrial stress. (PMID:27789709)
• A novel PPRC1 point mutation in a Chinese family with premature ovarian failure: A case study. (PMID:33818872)
• Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma. (PMID:37109742)
• Blood DNA methylation and liver cancer in American Indians: evidence from the Strong Heart Study. (PMID:38010586)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pprc1	ENSDARG00000090337
danio_rerio	si:dkey-93h22.8	ENSDARG00000098666
mus_musculus	Pprc1	ENSMUSG00000055491
rattus_norvegicus	Pprc1	ENSRNOG00000018561
drosophila_melanogaster	srl	FBGN0037248

Paralogs (2): PPARGC1A (ENSG00000109819), PPARGC1B (ENSG00000155846)

Protein

Protein identifiers

Peroxisome proliferator-activated receptor gamma coactivator-related protein 1 — Q5VV67 (reviewed: Q5VV67)

Alternative names: PGC-1-related coactivator

All UniProt accessions (3): Q5VV67, E7EVG6, X6R7H2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a coactivator during transcriptional activation of nuclear genes related to mitochondrial biogenesis and cell growth. Involved in the transcription coactivation of CREB and NRF1 target genes.

Subunit / interactions. Interacts with CREB1 and NRF1.

Subcellular location. Nucleus.

Tissue specificity. Strongly expressed in heart and skeletal muscle, moderately in lung, placenta, intestine, liver, kidney, spleen, thymus, colon and brain. Also expressed in several oncocytic thyroid tumors.

Induction. Up-regulated by serum (at protein level).

Isoforms (2)

UniProt ID	Names	Canonical?
Q5VV67-1	1	yes
Q5VV67-2	2

RefSeq proteins (3): NP_001275656, NP_001275657, NP_055877* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034605	PGC-1	Family
IPR034834	PRC_RRM	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076

UniProt features (44 total): compositionally biased region 15, region of interest 12, modified residue 6, splice variant 3, sequence variant 3, sequence conflict 3, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VV67-F1	42.49	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 237, 536, 548, 1076, 1411, 1413

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis

MSigDB gene sets: 186 (showing top): AHRARNT_01, E2F_Q4_01, MAZ_Q6, NAGASHIMA_NRG1_SIGNALING_UP, BONCI_TARGETS_OF_MIR15A_AND_MIR16_1, SP1_Q2_01, WEI_MYCN_TARGETS_WITH_E_BOX, MYCMAX_01, GROSS_HYPOXIA_VIA_ELK3_UP, GROSS_HYPOXIA_VIA_HIF1A_UP, GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP, HIF1_Q3, SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, AACTTT_UNKNOWN

GO Biological Process (2): positive regulation of transcription by RNA polymerase II (GO:0045944), energy homeostasis (GO:0097009)

GO Molecular Function (5): transcription coactivator activity (GO:0003713), RNA binding (GO:0003723), nucleic acid binding (GO:0003676), transcription coregulator activity (GO:0003712), transcription factor binding (GO:0008134)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Mitochondrial biogenesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of DNA-templated transcription	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
multicellular organismal-level homeostasis	1
transcription coregulator activity	1
nucleic acid binding	1
binding	1
transcription regulator activity	1
protein binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2258 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPRC1	TFAM	Q00059	750
PPRC1	NRF1	Q16656	578
PPRC1	PPARG	P37231	574
PPRC1	SLC25A3	Q00325	542
PPRC1	CIAO3	Q9H6Q4	519
PPRC1	S100A6	P06703	507
PPRC1	SIRT1	Q96EB6	462
PPRC1	PPARD	Q03181	461
PPRC1	HCFC1	P51610	456
PPRC1	FKBP14	Q9NWM8	450
PPRC1	ANKRD36	A6QL64	439
PPRC1	NFE2L2	Q16236	429
PPRC1	NAB1	Q13506	424
PPRC1	TFB2M	Q9H5Q4	407
PPRC1	TFB1M	Q8WVM0	406

IntAct

19 interactions, top by confidence:

A	B	Type	Score
CA10	WDHD1	psi-mi:“MI:0914”(association)	0.640
PIP4K2A	AP3B1	psi-mi:“MI:0914”(association)	0.530
SNRPC	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
EPB41L1	AP3B1	psi-mi:“MI:0914”(association)	0.530
ESR2	FBLL1	psi-mi:“MI:0914”(association)	0.460
ZMYND11	PPRC1	psi-mi:“MI:0407”(direct interaction)	0.440
	PPRC1	psi-mi:“MI:0915”(physical association)	0.370
Tubgcp6	MRE11	psi-mi:“MI:0914”(association)	0.350
Ncbp2	ZC3H18	psi-mi:“MI:0914”(association)	0.350
Ncbp2	EFCAB5	psi-mi:“MI:0914”(association)	0.350
NCBP2	SEH1L	psi-mi:“MI:0914”(association)	0.350
ZNF460	ZNF320	psi-mi:“MI:0914”(association)	0.350
SRSF7	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
PPRC1	ELOC	psi-mi:“MI:0915”(physical association)	0.000
PPRC1	degP	psi-mi:“MI:0915”(physical association)	0.000
CLIC6	PPRC1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (28): PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Two-hybrid), PPRC1 (Affinity Capture-RNA), NRF1 (Reconstituted Complex), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS), PPRC1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0A6YY25, A6NGG8, A6X8Z5, B2RQL2, B2RXH4, D3ZMK9, D3ZUE1, E9Q7F2, O08696, O14513, P59598, P97691, Q05860, Q05AH6, Q08050, Q0GGX2, Q0VET5, Q13029, Q2M1Z3, Q3U0P1, Q571I4, Q5PSV9, Q5SSG4, Q5U2M8, Q5VV67, Q63755, Q66H04, Q68DA7, Q69ZL1, Q6DIA7, Q6JPI3, Q6P1D7, Q6PAC4, Q6PG16, Q71F56, Q76N32, Q811R2, Q86YN6, Q86YV5, Q8BJS7

Diamond homologs: O70343, Q5VV67, Q6NZN1, Q811R2, Q865B6, Q865B7, Q86YN6, Q8VHJ7, Q9QYK2, Q9UBK2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

276 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	220
Likely benign	32
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

2045 predictions. Top by Δscore:

Variant	Effect	Δscore
10:102133305:G:GT	donor_gain	1.0000
10:102137842:T:A	acceptor_gain	1.0000
10:102137844:CTCCA:C	acceptor_loss	1.0000
10:102137845:TCCA:T	acceptor_loss	1.0000
10:102137846:CCA:C	acceptor_loss	1.0000
10:102137847:CA:C	acceptor_loss	1.0000
10:102137848:A:AT	acceptor_loss	1.0000
10:102137849:G:A	acceptor_loss	1.0000
10:102138034:GAGAG:G	donor_gain	1.0000
10:102138036:GAG:G	donor_gain	1.0000
10:102138039:G:GC	donor_loss	1.0000
10:102138040:T:A	donor_loss	1.0000
10:102138973:G:GT	donor_gain	1.0000
10:102139095:TGCA:T	acceptor_loss	1.0000
10:102139097:CAG:C	acceptor_loss	1.0000
10:102139098:A:AG	acceptor_gain	1.0000
10:102139098:A:C	acceptor_loss	1.0000
10:102139099:G:GA	acceptor_loss	1.0000
10:102139099:G:GG	acceptor_gain	1.0000
10:102139099:GGTT:G	acceptor_gain	1.0000
10:102143042:CA:C	acceptor_loss	1.0000
10:102143043:A:AG	acceptor_gain	1.0000
10:102143043:AGG:A	acceptor_loss	1.0000
10:102143044:G:A	acceptor_loss	1.0000
10:102143044:G:GG	acceptor_gain	1.0000
10:102143044:GGA:G	acceptor_gain	1.0000
10:102143095:GAAG:G	donor_gain	1.0000
10:102143097:AG:A	donor_loss	1.0000
10:102143098:GGT:G	donor_loss	1.0000
10:102143099:GTGA:G	donor_loss	1.0000

AlphaMissense

10597 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:102148824:G:C	R1542T	1.000
10:102148824:G:T	R1542I	1.000
10:102148825:A:C	R1542S	1.000
10:102148825:A:T	R1542S	1.000
10:102148827:G:T	R1543M	1.000
10:102148828:G:C	R1543S	1.000
10:102148828:G:T	R1543S	1.000
10:102148833:T:A	V1545D	1.000
10:102148835:T:A	F1546I	1.000
10:102148835:T:C	F1546L	1.000
10:102148836:T:C	F1546S	1.000
10:102148837:C:A	F1546L	1.000
10:102148837:C:G	F1546L	1.000
10:102148839:T:A	I1547N	1.000
10:102148841:G:A	G1548R	1.000
10:102148841:G:C	G1548R	1.000
10:102148842:G:A	G1548E	1.000
10:102148842:G:T	G1548V	1.000
10:102148848:T:A	I1550K	1.000
10:102148848:T:C	I1550T	1.000
10:102148848:T:G	I1550R	1.000
10:102148875:T:A	L1559Q	1.000
10:102148875:T:C	L1559P	1.000
10:102148886:T:A	F1563I	1.000
10:102148886:T:C	F1563L	1.000
10:102148887:T:C	F1563S	1.000
10:102148888:C:A	F1563L	1.000
10:102148888:C:G	F1563L	1.000
10:102148895:T:A	F1566I	1.000
10:102148895:T:C	F1566L	1.000

dbSNP variants (sampled 300 via entrez): RS1000093356 (10:102143986 A>G,T), RS1000194324 (10:102150419 T>G), RS1000206814 (10:102120435 GC>G,GCC), RS1000223621 (10:102126297 G>A), RS1000266996 (10:102132124 G>A), RS1000304010 (10:102137542 C>T), RS1000435263 (10:102118944 T>C,G), RS1000526927 (10:102125025 C>T), RS1000635849 (10:102119367 T>C), RS1000782988 (10:102143034 T>C), RS1000909355 (10:102136054 G>A,C), RS1000918684 (10:102142841 C>T), RS1000993270 (10:102131355 C>T), RS1001035642 (10:102130306 G>A,T), RS1001066683 (10:102131057 T>C)

Disease associations

OMIM: gene MIM:617462 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST004630_242	Mean corpuscular hemoglobin	8.000000e-13
GCST009391_1637	Metabolite levels	4.000000e-06
GCST90002390_495	Mean corpuscular hemoglobin	7.000000e-28
GCST90002390_496	Mean corpuscular hemoglobin	1.000000e-12
GCST90002392_549	Mean corpuscular volume	5.000000e-15
GCST90002396_494	Mean reticulocyte volume	4.000000e-10
GCST90002397_549	Mean spheric corpuscular volume	9.000000e-27

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0007787	plasma betaine measurement
EFO:0010701	mean reticulocyte volume

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects binding, increases reaction, increases expression	4
Cyclosporine	increases expression, increases methylation	3
bisphenol A	affects binding, affects folding, increases reaction, decreases reaction	2
sodium arsenite	decreases expression	2
(+)-JQ1 compound	decreases expression	2
Cisplatin	affects cotreatment, decreases expression	2
Formaldehyde	decreases expression	2
Nickel	increases expression	2
Tretinoin	decreases expression	2
Valproic Acid	increases methylation, affects expression	2
Aflatoxin B1	affects expression, increases expression	2
Cadmium Chloride	decreases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
trichostatin A	affects expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	increases expression, affects cotreatment	1
chloropicrin	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
abrine	increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
bisphenol S	affects binding, decreases reaction	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer